FDA Grants Orphan-Drug Status to Lorus Lead Anticancer Drug

The FDA has granted orphan-drug status to Lorus Therapeutics' GTI-2040, the company's lead anticancer drug for the treatment of acute myeloid leukemia (AML).

GTI-2040 received orphan-drug status for renal cell carcinoma in 2004. In partnership with the National Cancer Institute's Cancer Therapy Evaluation Program, GTI 2040 is currently being investigated in a Phase II clinical trials program for AML, breast cancer, lung cancer, prostate cancer, colon cancer and a variety of solid tumors.